Western blot detection kits are used to demonstrate the reaction of HCP antibodies with the majority of HCPs present in a given cell line or in a purification process. However, due to sensitivity limitations, coverage can only be estimated in samples collected upstream where HCPs are still within the sensitivity limitations of various staining methods.
Western blot detection kits provide limited predictive value in determining how the ELISA WESTERN BLOT KITS using that antibody will react quantitatively to the more limited range of HCP in subsequent samples.
Please see our Custom Development Services pages for more information on Antibody Affinity Extraction (AAE), a superior method for antibody coverage analysis and the identification of individual healthcare professionals who could be co-purified with the drug.
Western blot (WB) assays have traditionally been used to demonstrate that HCP antibodies react with most HCPs present in a given cell line or in a purification process. Due to the sensitivity limitations of WB, coverage can only be estimated in upstream collection samples where HCPs are still within the sensitivity limitations of various staining methods. WB provides limited predictive value to determine how the ELISA using that antibody will react quantitatively to the more limited range of HCP in subsequent samples.